Albuminuria Clinical Trial
Official title:
Effects of Intensive Low-Salt Diet Education by Mobile Application on Albuminuria
NCT number | NCT03396328 |
Other study ID # | 4-2017-0906 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | May 10, 2018 |
Est. completion date | May 12, 2020 |
Verified date | September 2020 |
Source | Yonsei University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Albuminuria is a known risk factor for cardiovascular disease (CVD), chronic kidney disease
(CKD) progression, all cause mortality. Inhibition of the renin-angiotension-aldosterone
system (RAAS) plays an important role in the reduction of albuminuria and preservation of
renal function in patients with CKD and it is known that the daily intakes of sodium have a
significant effect on the activity of RAAS. Dietary sodium restriction has been shown to
enhances the blood pressure, albuminuria, and renal function preservation. Furthermore,
recent study has shown that intensive low-salt dietary education reduces albuminuria in
patients with CKD. The average sodium intake of Koreans is 4,791 mg/d, which is higher than
other countries. It is difficult for medical staff in Korea to invest enough time in low salt
diet.
Recently, the development of health-related applications (apps) has been carried out
worldwidely, and researches on lifestyle improvement using apps have been actively studied.
However, there is no research yet on whether intensive education using an apps can affect
lifestyle habits and thus changes in actual new features. Smartphone apps may provide an
alternative to resource-intensive low salt diet-education. Therefore, this study aims to
investigate the effect of intensive low salt diet training on the changes of albuminuria
using application.
Status | Completed |
Enrollment | 108 |
Est. completion date | May 12, 2020 |
Est. primary completion date | May 12, 2020 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 19 Years to 65 Years |
Eligibility |
Inclusion Criteria: - Age : 19-65 - Underlying hypertension or antihypertensive medication , or Systolic blood pressure ? 140 mmHg or Diastolic blood pressure ? 90 - Modification of Diet in Renal Disease study (MDRD) eGFR ? 30 ml/min per 1.73m2 - Random urine albumin-to-creatinine ratio ? 30 mg/g - Smartphone ownership Exclusion Criteria: - Age under 18 or over 66 - Uncontrolled hypertension (BP>160/110 mmHg) - Pregnancy within 6 months - Serum potasium > 5.5 mEq/L - malignancy - a diagnosis of CVD (cerebral infarction, hemorrhagic infarction, acute myocardial infarction or unstable angina, coronary angioplasty, or coronary artery bypass surgery) within the last 6 months - Contraindication to angiotensin II receptor blocker - life expectancy less than 6 months |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Division of Nephrology, Department of Internal Medicine Yonsei University College of Medicine | Seoul |
Lead Sponsor | Collaborator |
---|---|
Yonsei University |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Decrements of 24-hour urine albumin levels | Decrements of 24-hour urine albumin levels 12 weeks after low salt diet education | 12 weeks after low salt diet education start | |
Secondary | Decrements of 24-hour urine sodium | 12 weeks after low salt diet education start | ||
Secondary | Change of blood pressure with a sphygmomanometer | 12 weeks after low salt diet education start |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00095290 -
Irbesartan Versus Placebo in Combination With Ramipril for Treatment of Albuminuria
|
Phase 4 | |
Completed |
NCT02144740 -
Effect of NWT-03 on Blood Pressure
|
N/A | |
Completed |
NCT01041599 -
Correlation of Albuminuria With Arterial Stiffness
|
N/A | |
Active, not recruiting |
NCT05321095 -
Screening for Albuminuria at the First Line for Early Identification of CKD
|
||
Completed |
NCT02945969 -
Sodium Lowering and Urinary Protein Reduction Trial
|
Phase 3 | |
Enrolling by invitation |
NCT04295889 -
Towards HOMe-based Albuminuria Screening: an Implementation Study Testing Two Approaches
|
N/A | |
Recruiting |
NCT04272359 -
Substitution of Sulfonylureas With New Generation of Hypoglycemic Drugs for the Treatment of Type 2 Diabetes Mellitus
|
||
Completed |
NCT03889236 -
Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy.
|
N/A | |
Active, not recruiting |
NCT00625820 -
Tetrahydrobiopterin in Patients With Chronic Kidney Disease (CKD) and Albuminuria
|
Phase 2 | |
Recruiting |
NCT04752293 -
Pediatric Hypertension and the Renin-Angiotensin SystEm (PHRASE)
|
||
Completed |
NCT03118739 -
Intensive Uric Acid Lowering With Verinurad and Febuxostat in Patients With Albuminuria
|
Phase 2 | |
Completed |
NCT06374043 -
Decentralized N=1 Study: A Feasible Approach to Evaluate Individual Therapy Response to Dapagliflozin.
|
Phase 4 | |
Not yet recruiting |
NCT06094920 -
Treatment Optimization for Patients With Type 2 Diabetes Using Empagliflozin and Finerenone in a Remote Clinical Trial
|
Phase 4 | |
Recruiting |
NCT00342927 -
Family Investigation of Nephropathy and Diabetes (F.I.N.D.)
|
||
Completed |
NCT02689778 -
Effect of Pirfenidone on Glomerular Filtration Rate and Albuminuria in Patients With Diabetic Nephropathy
|
Phase 3 | |
Completed |
NCT02497300 -
Vascular Effects of Mineralocorticoid Receptor Antagonism in Kidney Disease
|
Phase 2 | |
Completed |
NCT02446548 -
Influence of Aliskiren on Albuminuria After Kidney Transplantation
|
N/A | |
Completed |
NCT01547897 -
NOX-E36 in Patients With Type 2 Diabetes Mellitus and Albuminuria
|
Phase 2 | |
Enrolling by invitation |
NCT01316068 -
Effect of Sulodexide on Albuminuria in Chinese Type 2 Diabetic Patients
|
Phase 4 | |
Completed |
NCT00312780 -
Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy
|
Phase 2 |